I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers in the United States

I-Mab Biopharma (“I-Mab”), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces on June 24, 2019, that the first patient has...

Read more
Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies

Target Health and dMed Biopharmaceuticals Join Forces to Help Western and Chinese Biopharma and Device Companies

Target Health Inc. and dMed Biopharmaceuticals Company Limited have joined forces to help Western and Chinese biopharma and device companies capitalize on the rapid internationalization of clinical trials between the US and China while...

Read more
Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region

Terns Pharmaceuticals Announces Exclusive Licensing and Collaboration Agreement with GENFIT to Develop and Commercialize Elafibranor in the Greater China Region

Terns Pharmaceuticals, Inc. today announced an exclusive licensing and collaboration agreement with GENFIT (GNFT), a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic...

Read more
CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment

CASI Acquires Global Rights To CD19 T-Cell Therapy; Will Make $11.6 Million Investment

CASI Pharma, a US-China company, obtained global rights to an autologous anti-CD19 T-cell therapy developed by Juventas Cell Therapy of Tianjin City, China. Juventas has filed China INDs to test CNCT19 as a treatment for two leukemia and lymphoma...

Read more
Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia

Jiangsu Hengrui In-Licenses Treatment for Yeast Infection from Mycovia

Jiangsu Hengrui Medicine in-licensed greater China rights to a treatment for chronic yeast infections from Mycovia Pharma of Durham, North Carolina. Mycovia is currently conducting a Phase III trial of VT-1161 (otesaconazole) in women with...

Read more
Hansoh Completes $1 Billion Hong Kong IPO; Rises 37% in First Trading Session

Hansoh Completes $1 Billion Hong Kong IPO; Rises 37% in First Trading Session

Hansoh Pharma completed a highly successful Hong Kong IPO, pricing last week at the top end of its range, and then following up with a 37% rise in its first trading session today. The IPO raised $1 billion for the company at a valuation of $10.7...

Read more
Reistone Starts Global Trial of China-Discovered JAK1 Inhibitor for IBD

Reistone Starts Global Trial of China-Discovered JAK1 Inhibitor for IBD

Reistone, a one-year-old Shanghai-Beijing-Boston biopharma, has dosed the first patient in global Phase II trial of its JAK1 inhibitor in patients with Ulcerative Colitis and Crohn’s disease. The JAK1 candidate was developed by Jiangsu...

Read more
MORE Health Announces Strategic Collaboration with Memorial Sloan Kettering Cancer Center

MORE Health Announces Strategic Collaboration with Memorial Sloan Kettering Cancer Center

MORE Health, Inc., a global healthcare company, today announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK), the world’s oldest and largest private cancer center, that gives patients from across the world...

Read more
Tessa Forms $120 Million China JV to Develop Cell Therapies for Cancer

Tessa Forms $120 Million China JV to Develop Cell Therapies for Cancer

Tessa Therapeutics, a Singapore company, will form a $120 million JV with China-Singapore Guangzhou Knowledge City (CSGKC) to develop Tessa’s oncology cell therapies in China. The companies will fund the JV in two stages, with Tessa...

Read more
Terns Starts US Trial of Lead Drug, a NASH Candidate

Terns Starts US Trial of Lead Drug, a NASH Candidate

Terns Pharma, a Silicon Valley-Shanghai company, started a US Phase I clinical trial of TERN-101 to treat non-alcoholic steatohepatitis (NASH). TERN-101 is a farnesoid X receptor (FXR) agonist. One year ago, Terns in-licensed three drug...

Read more
Proton Clinical Research Center of the Shandong Cancer Hospital First APAC Member of FlashForward Consortium

Proton Clinical Research Center of the Shandong Cancer Hospital First APAC Member of FlashForward Consortium

Varian Medical (NYSE: VAR) today announced the Proton Clinical Research Center of the Shandong Cancer Hospital, is the first center in Asia Pacific to join the FlashForward™ Consortium. The Consortium now includes 15 institutions and is focused...

Read more
Parexel Teams with CLARINESS to Enhance Patient Access and Engagement in China

Parexel Teams with CLARINESS to Enhance Patient Access and Engagement in China

PAREXEL, a leader in the development of innovative new therapies to improve the world’s health, today announced a strategic partnership with Clariness, a leading global patient recruitment company, to further accelerate clinical trial recruitment...

Read more
Do NOT follow this link or you will be banned from the site!